THOUSAND OAKS, Calif.,
May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.
"The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "As a company rooted in biology, we are in a strong position to develop innovative therapies that fight cancer through new pathways such as immunotherapy and to leverage biomarkers to advance personalized medicine."
Meeting delegates who visit Amgen's booth will also have the opportunity to learn more about Amgen's legacy of manufacturing expertise – from research and development to delivery of complex biological therapies.
Abstracts are currently available on the ASCO website at
ABSTRACTS OF INTEREST INCLUDE:
The results of the primary analysis of the pivotal trial of talimogene laherparepvec, an investigational oncolytic immunotherapy for the treatment of melanoma, including interim overall survival data, will be presented.
OPTiM: A Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) versus Subcutaneous (SC)
Granulocyte-Macrophage Colony-Stimulating Factor (
GM-CSF) for the Treatment (tx) of Unresected Stage IIIB/C and IV MelanomaAbstract No. LBA9008, Oral Presentation,
Saturday, June 1,
3:45 p.m. CDT, S406
Results from a Phase 1 study in pediatric patients with acute lymphoblastic leukemia (ALL) will be presented for blinatumomab, the first of a new investigational class of agents designed to harness the body's cytotoxic T cells to kill cancer cells.
Cytological and Molecular Remissions With Blinatumomab Treatment in Second or Later Bone Marrow Relapse in Pediatric Acute Lymphoblastic Leukemia (ALL) Abstract No. 10007, Oral Presentation,
Sunday, June 2,
10:30 a.m. CDT, S504
Three new analyses of trials studying Vectibix in combination with FOLFOX, an oxaliplatin-based chemotherapy, as a first-line treatment for metastatic colorectal cancer (mCRC) will be presented. Presentations include two analyses of the Phase 3 PRIME ('203) trial: an updated overall survival analysis and an analysis of the treatment effect by
status, respectively. The Phase 3 PRIME ('203) trial evaluated Vectibix plus FOLFOX versus FOLFOX alone in patients with wild-type
An analysis by
status of the Phase 2 PEAK ('509) trial comparing the efficacy of Vectibix in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX in patients with wild-type
mCRC will also be presented.
About Talimogene Laherparepvec
Overall Survival (OS) Analysis from PRIME: Randomized Phase 3 Study of panitumumab (pmab) with FOLFOX4 for First-line Metastatic Colorectal Cancer (mCRC) Abstract No. 3620, Poster,
Sunday, June 2,
8:00 a.m. CDT, S Hall A2
KRAS/NRAS Mutations in PEAK: A Randomized Phase II Study of FOLFOX6 plus Panitumumab (pmab) or Bevacizumab (bev) as First-line Treatment (tx) for Wild-
KRAS (exon 2) Metastatic Colorectal Cancer (mCRC)Abstract No. 3631, Poster,
Sunday, June 2,
8:00 a.m. CDT, S Hall A2
Analysis of KRAS/NRAS and BRAF Mutations in the Phase 3 PRIME Study of Panitumumab (pmab) + FOLFOX vs FOLFOX as First-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC)Abstract No. 3511, Poster Discussion,
Tuesday, June 4,
8:00 a.m. CDT, S405
Talimogene laherparepvec is an investigational oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate within cancer cells and to produce GM-CSF to enhance systemic antitumor immune responses. Talimogene laherparepvec is injected directly into tumor tissue and replicates until the membranes of the cancer cells rupture, thereby destroying them in a process known as oncolysis. The virus contained in these cells as well as potential tumor antigens are then released locally along with GM-CSF, a white blood cell growth factor that the virus is engineered to express. This is intended to activate antigen presenting cells and elicit a systemic immune response to kill tumor cells throughout the body.
Blinatumomab is an investigational bi-specific T cell engager (BiTE
) antibody designed to direct the body's cytotoxic T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells with cancer cells. Blinatumomab is the first of the BiTE antibodies, and Amgen has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and indolent B cell lymphoma and from the European Medicines Agency for the treatment of indolent B cell lymphoma, ALL, CLL and mantle cell leukemia (MCL).
Vectibix is the first fully human anti-epidermal growth factor receptor (EGFR) antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC). Vectibix was approved in
the United States
as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.
Important U.S. Product Information
Vectibix is indicated as a single agent for the treatment of EGFR-expressing, mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing mCRC is based on progression-free survival. Currently, no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.
Vectibix is not indicated for the treatment of patients with
mutation-positive mCRC or for whom
mCRC status is unknown. Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had
mutations in codon 12 or 13.
WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS
Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of patients and were severe (NCI-CTC grade 3 or higher) in 12 percent of patients receiving Vectibix monotherapy. [See Dosage and Administration (2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].
Infusion Reactions: Severe infusion reactions occurred in approximately one percent of patients. Fatal infusion reactions occurred in postmarketing experience. [See Dosage and Administration (2.1), Warnings and Precautions (5.2), and Adverse Reactions (6.1, 6.3)].